Keywords: Bayer, Regeneron, VEG Trap-Eye, Macular edema, Research
Strong Ph II results for Regeneron/Bayer’s VEG Trap-Eye macular edema drug
Article | 19 February 2010
USA-based Regeneron Pharmaceuticals and partner Bayer HealthCare of Germany announced that VEGF Trap-Eye showed positive results in a Phase II ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
